Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GT103 in refractory advanced NSCLC
NCT04314089Phase 1Completed
- Start
- Jun 2020
- Primary completion
- Apr 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of GT103 in non-small cell lung cancer (NSCLC). Primary endpoints: Maximum Tolerated Dose at 2 years and Time for the concentration of GT103 to reach half of the level administered at 2 years. Started Jun 2020; status: completed.
02
Drugs
GT103
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04314089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04314089.